Rice Hall James & Associates LLC Boosts Holdings in OptimizeRx Co. (NASDAQ:OPRX)

Rice Hall James & Associates LLC boosted its stake in OptimizeRx Co. (NASDAQ:OPRX - Free Report) by 24.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 615,441 shares of the company's stock after buying an additional 119,306 shares during the quarter. Rice Hall James & Associates LLC owned approximately 3.36% of OptimizeRx worth $4,751,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Connors Investor Services Inc. lifted its stake in shares of OptimizeRx by 15.1% in the second quarter. Connors Investor Services Inc. now owns 19,107 shares of the company's stock worth $191,000 after buying an additional 2,500 shares in the last quarter. Summit Securities Group LLC acquired a new stake in shares of OptimizeRx in the second quarter valued at approximately $25,000. Rhumbline Advisers lifted its position in OptimizeRx by 9.2% during the second quarter. Rhumbline Advisers now owns 31,462 shares of the company's stock worth $315,000 after buying an additional 2,658 shares in the last quarter. Vanguard Group Inc. grew its holdings in OptimizeRx by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 1,027,293 shares of the company's stock valued at $12,482,000 after buying an additional 6,291 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its stake in shares of OptimizeRx by 9.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 111,719 shares of the company's stock worth $1,117,000 after acquiring an additional 10,041 shares during the last quarter. 76.47% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have commented on OPRX. Royal Bank of Canada reduced their target price on shares of OptimizeRx from $17.00 to $14.00 and set an "outperform" rating on the stock in a research note on Friday, August 16th. B. Riley initiated coverage on OptimizeRx in a research report on Thursday, July 25th. They issued a "buy" rating and a $18.50 price objective for the company. Finally, Barclays reduced their target price on OptimizeRx from $15.00 to $11.00 and set an "equal weight" rating on the stock in a research report on Monday, August 12th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $14.50.

OptimizeRx Trading Down 1.3 %

Shares of NASDAQ OPRX traded down $0.07 during trading on Friday, reaching $5.15. The stock had a trading volume of 111,170 shares, compared to its average volume of 127,196. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.07 and a current ratio of 3.07. The company has a market cap of $94.35 million, a P/E ratio of -5.18 and a beta of 1.27. OptimizeRx Co. has a fifty-two week low of $5.14 and a fifty-two week high of $16.65. The business's 50-day moving average price is $7.18 and its 200-day moving average price is $9.30.

OptimizeRx (NASDAQ:OPRX - Get Free Report) last released its earnings results on Thursday, August 8th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.11. The company had revenue of $18.81 million during the quarter, compared to the consensus estimate of $20.47 million. OptimizeRx had a negative return on equity of 5.97% and a negative net margin of 21.53%. On average, equities research analysts predict that OptimizeRx Co. will post -0.33 EPS for the current fiscal year.

OptimizeRx Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.